ID
PFE icon

Integral Derivatives’s Pfizer PFE Stock Holding History

Integral Derivatives’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-34,299
Closed -$1.17M – 1254
2017
Q3 		$1.16M Sell
34,299
-15,705
-31% -$505K 0.02% 444
2017
Q2 		$1.59M Buy
50,004
+18,340
+58% +$578K 0.03% 359
2017
Q1 		$1.03M Buy
31,664
+15,125
+91% +$477K 0.02% 514
2016
Q4 		$510K Buy
16,539
+643
+4% +$19.6K 0.01% 720
2016
Q3 		$511K Sell
15,896
-17,497
-52% -$585K 0.01% 626
2016
Q2 		$1.12M Buy
+33,393
New +$1.07M 0.03% 386
2015
Q1 		– Sell
-17,344
Closed -$551K – 1326
2014
Q4 		$513K Buy
+17,344
New +$497K 0.01% 913
2014
Q3 		– Sell
-53,970
Closed -$1.51M – 1512
2014
Q2 		$1.52M Buy
53,970
+41,447
+331% +$1.18M 0.03% 524
2014
Q1 		$382K Buy
+12,523
New +$373K 0.01% 971

Other funds holding PFE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Integral Derivatives's PFE Position: Q4 2017 in Review

Integral Derivatives sold out of Pfizer (PFE) in Q4 2017, closing a stake of 34,299 shares — an estimated $1.17M sold.

Integral Derivatives first reported a position in PFE in Q1 2014 and held it in 9 quarters. The position peaked at $1.59M in Q2 2017. 2,244 funds tracked by Wall St. Rank hold PFE as of Q4 2017.

  • Integral Derivatives reported no remaining Pfizer position as of Q4 2017 after selling out during the quarter.
  • Integral Derivatives sold 34,299 Pfizer shares in Q4 2017, an estimated $1.17M.
  • Integral Derivatives first reported a position in Pfizer in Q1 2014 and held it in 9 quarters.
  • Integral Derivatives's Pfizer position peaked at $1.59M in Q2 2017.
  • 2,244 funds tracked by Wall St. Rank held Pfizer as of Q4 2017.

Based on Integral Derivatives's 13F filing for Q4 2017, filed 14 Feb 2018.